Physician profile
Stan A Messner
NPI 1780792804
$5,297.05
in general payments reported to CMS, 2019-2025
38 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $462 · 2021: $1,144 · 2022: $876 · 2023: $489 · 2024: $843 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $857.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $668.65 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $564.12 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $513.47 | 2019-2024 | |
| Novo Nordisk INC | $429.60 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.99 | 2019-2025 | Jardiance, Ofev |
| Medtronic, INC. | $190.94 | 2021-2025 | Intellis Adaptivestim, Symplicity G3 |
| Amarin Pharma, INC. | $178.43 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $178.08 | 2019-2022 | |
| Lilly USA, LLC | $122.11 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Eisai INC. | $121.39 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $118.00 | 2021 | |
| Sumitomo Pharma America, INC. | $117.47 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $96.16 | 2019-2025 | |
| Abbott Laboratories | $87.56 | 2021-2025 | Freestyle Libre 3 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stan Messner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.